Kunpeng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kunpeng Zhang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Ding Yang
Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
5 shared publications - Qiang Li
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Qiuling Shi
School of Public Health, Chongqing Medical University, Chongqing, People’s Republic of China
5 shared publications - Wei Dai
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Xing Wei
Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Hongfan Yu
Department of Pharmacy, The First Affiliated Hospital of Army Medical University, Third Military Medical University, Chongqing, China
4 shared publications
Latest Publications
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4288-4300
Long-Term Patient-Reported Outcomes after Multiport Robot-Assisted Surgery versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
The purpose of this study was to compare patient-reported outcomes (PROs) and perioperative clinical outcomes during 1 year post surgery between robot-assi
- 10 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4288-4300
Long-Term Patient-Reported Outcomes after Multiport Robot-Assisted Surgery versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
The purpose of this study was to compare patient-reported outcomes (PROs) and perioperative clinical outcomes during 1 year post surgery between robot-assi
- 9 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4360-4361
ASO Visual Abstract: Long-Term Patient-Reported Outcomes After Multiport Robot-Assisted Surgery Versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
- 9 February 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (5) , 4360-4361
ASO Visual Abstract: Long-Term Patient-Reported Outcomes After Multiport Robot-Assisted Surgery Versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study
- Open Access
- 29 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 2834-2836
Expanding Surgical Boundaries in Pseudomyxoma Peritonei: The Emerging Role of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for Pleural Metastases
- 29 December 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (4) , 2834-2836
Open AccessExpanding Surgical Boundaries in Pseudomyxoma Peritonei: The Emerging Role of Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy for Pleural Metastases
- Open Access
Protocol of an iterative qualitative study to develop a molecular testing decision aid for shared decision-making in patients with lung cancer after surgery
Introduction Although molecular testing is crucial for many patients with lung cancer, the decision to carry out molecular testing is not easy to make in actual clinical scenarios. Using a specific decision aid (DA) to conduct shared decision-making (SDM) may help ameliorate this problem. However, no DA currently exists for lung cancer molecular testing (DA_LCMT). We aim to develop an evidence-based, iteratively refined DA, which may facilitate SDM and improve the quality of SDM. Methods and analysis After considering the Ottawa Decision Support Framework, International Patient Decision Aid Standards and Food and Drug Administration guidance about methods to identify what is important to patients, semistructured interviews with qualitative research methods will be used to generate the decision-making needs of patients with lung cancer diagnosed with lung adenocarcinoma by intraoperative frozen pathological sections. Input will be provided by patients and other stakeholders, including thoracic surgeons, nurses, hospital administrators, molecular testing company staff and insurance company staff. Then, a modified Delphi method will be used to develop the DA_LCMT V.1.0 (DA_LCMT 1.0). Structured interviews with qualitative research methods will be used in the cognitive debriefing (alpha tests) and field testing (beta tests) to revise and improve the DA_LCMT from version 1.0 to the final version, version 3.0. Descriptive statistics will be used to summarise the baseline characteristics of the patients and other stakeholders. Qualitative data will be analysed using the three steps of grounded theory: generate a codebook, update the codebook and create a comprehensive list of related items. Ethics and dissemination Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study. This protocol is based on the latest version 1.0, dated 31 October 2021. The study was also approved by the Ethics Committees of The Third People’s Hospital of Chengdu, Zigong First People’s Hospital and Jiangyou People’s Hospital. The results of this study will be presented at medical conferences and published in peer-reviewed journals. Trial registration number NCT05191485.
Open AccessProtocol of an iterative qualitative study to develop a molecular testing decision aid for shared decision-making in patients with lung cancer after surgery
Introduction Although molecular testing is crucial for many patients with lung cancer, the decision to carry out molecular testing is not easy to make in actual clinical scenarios. Using a specific decision aid (DA) to conduct shared decision-making (SDM) may help ameliorate this problem. However, no DA currently exists for lung cancer molecular testing (DA_LCMT). We aim to develop an evidence-based, iteratively refined DA, which may facilitate SDM and improve the quality of SDM. Methods and analysis After considering the Ottawa Decision Support Framework, International Patient Decision Aid Standards and Food and Drug Administration guidance about methods to identify what is important to patients, semistructured interviews with qualitative research methods will be used to generate the decision-making needs of patients with lung cancer diagnosed with lung adenocarcinoma by intraoperative frozen pathological sections. Input will be provided by patients and other stakeholders, including thoracic surgeons, nurses, hospital administrators, molecular testing company staff and insurance company staff. Then, a modified Delphi method will be used to develop the DA_LCMT V.1.0 (DA_LCMT 1.0). Structured interviews with qualitative research methods will be used in the cognitive debriefing (alpha tests) and field testing (beta tests) to revise and improve the DA_LCMT from version 1.0 to the final version, version 3.0. Descriptive statistics will be used to summarise the baseline characteristics of the patients and other stakeholders. Qualitative data will be analysed using the three steps of grounded theory: generate a codebook, update the codebook and create a comprehensive list of related items. Ethics and dissemination Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital approved this study. This protocol is based on the latest version 1.0, dated 31 October 2021. The study was also approved by the Ethics Committees of The Third People’s Hospital of Chengdu, Zigong First People’s Hospital and Jiangyou People’s Hospital. The results of this study will be presented at medical conferences and published in peer-reviewed journals. Trial registration number NCT05191485.